<DOC>
	<DOCNO>NCT00437073</DOCNO>
	<brief_summary>This study patient ErbB2 overexpressing breast cancer spread brain still progress even radiation treatment use WBRT ( whole brain radiotherapy ) SRS ( stereotactic radiosurgery ) brain . The study determine safe effective lapatinib give combination capecitabine treat patient ErbB2 overexpressing breast cancer spread brain . Lapatinib oral drug take every day . Tests safety efficacy perform regularly course study .</brief_summary>
	<brief_title>Brain Metastases In ErbB2-Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Inclusion criterion : Subjects eligible enrollment study must meet following criterion : Signed write informed consent ; Females males age ≥ 18 year old ; Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 ; Life expectancy least 12 week ; Subjects must histologically cytologically confirm invasive breast cancer , Stage IV disease ; ErbB2 overexpressing breast cancer , define 3+ stain immunohistochemistry ( IHC ) , 2+ stain IHC conjunction ErbB 2 gene amplification FISH , ErbB 2 gene amplification FISH alone ( subject whose tumor block assess IHC ) . Subjects tumor 2+ IHC negative borderline FISH assay ineligible . For subject history one primary breast cancer , breast cancer must ErbB2 overexpressing eligible ; ErbB2 overexpressing breast cancer , define 3+ stain immunohistochemistry ( IHC ) , 2+ stain IHC conjunction ErbB2 gene amplification FISH , ErbB2 gene amplification FISH alone ( subject whose tumor block assess IHC ) . ErbB2 gene amplification define : &gt; 6 ErbB2 gene copies/nucleus test system without internal control probe ErbB2/CEP 17 ratio 2.2 . Subjects tumor 2+ IHC negative borderline FISH assay ineligible . For subject history one primary breast cancer , breast cancer must ErbB2 overexpressing eligible ; Prior treatment brain metastasis WBRT and/or SRS ; Unequivocal evidence new / progressive lesion brain imaging study ; Note : Subjects progressive brain lesion require meet RECIST criterion CNS progression order eligible study . Prior treatment trastuzumab , either alone combination chemotherapy require . Trastuzumab discontinue least 2 week prior enrollment study ; Cardiac ejection fraction within institutional range normal measure echocardiogram . Subjects require cardiac medication ( e.g . positive inotropic agent afterload reducer ) normal ejection fraction ineligible . MUGA scan accept case echocardiogram perform inconclusive ; At least 2 week since prior radiotherapy , last chemotherapy , immunotherapy , biologic therapy , hormonal therapy cancer , sufficiently recover stabilized side effect associate prior therapy . Concurrent treatment bisphosphonates permit ; At least 3 week since major surgical procedure ; Able swallow retain oral medication ; Women childbearing potential must negative serum pregnancy test screening must use approved contraceptive method , appropriate ( example , intrauterine device [ IUD ] , birth control pill , barrier device ) begin 2 week first dose investigational product 28 day final dose investigational product . Males able father child must practice adequate method birth control practice complete abstinence intercourse first dose investigational treatment one week final dose investigational treatment . Subjects must complete screen assessment outline protocol ; Normal organ marrow function define LABORATORY VALUES : ANC ( absolute neutrophil count ) ≥ 1.5 x 10^9/L ; Hemoglobin ≥ 10 g/dL ( transfusion need ) ; Platelets ≥ 100 x 10^9/L ; Albumin ≥ 2.5 g/dL ; Serum bilirubin ≤ 1.5x ULN unless due Gilbert 's syndrome ; AST ALT ≤ 5x ULN document liver metastasis ≤ 3x ULN without liver metastasis ; Serum Creatinine ≤ 1.2 mg/dL Calculated Creatinine Clearance1 ≥ 50 mL/min Subjects meet follow criterion must enrol study : Subjects chemotherapy radiotherapy within 2 week prior enter study unresolved unstable , serious toxicity prior administration another investigational drug and/or prior cancer treatment ; Concurrent treatment investigational agent participation another treatment clinical trial ; Prior therapy topoisomerase 1 inhibitor ; Prior lapatinib therapy ; Prior therapy capecitabine ; Known dihydropyrimidine dehydrogenase ( DPD ) deficiency ; ECOG Performance Status 2 great ; Subjects receive concurrent chemotherapy , radiation therapy , immunotherapy , biologic therapy ( include ErbB1 and/or ErbB2 inhibitor ) , hormonal therapy treatment cancer . Hormone therapy ovarian suppression use &gt; 6 month , time disease progression brain , allow . Concurrent treatment bisphosphonates allow ; Subjects evidence leptomeningeal carcinomatosis screening ; History allergic reaction attribute compound similar chemical composition ( quinazolines ) lapatinib ; History allergic reaction attribute compound chemically related capecitabine , fluorouracil excipients ; Concurrent treatment medication list Prohibited Medications ; Malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel . Subjects active , uncontrolled ulcerative colitis also exclude ; History immediate delay hypersensitivity reaction gadolinium contrast agent , contraindication gadolinium contrast ; Other know contraindication MRI , cardiac pacemaker , implanted cardiac defibrillator , brain aneurysm clip , cochlear implant , ocular foreign body , shrapnel ; Concurrent disease condition would make subject inappropriate study participation serious medical psychiatric disorder would interfere subject 's safety ; Anticoagulant therapy ( coumadin aspirin catheter prophylaxis ) study entry ; Dementia , alter mental status , psychiatric condition would prohibit understanding rendering informed consent , unless legally acceptable representative could provide informed consent ( accord policy local Ethics Committee ) ; Preexisting severe cerebral vascular disease , stroke involve major vessel , CNS vasculitis , malignant hypertension ; Active cardiac disease , define one following : History uncontrolled symptomatic angina History arrhythmia require medication , clinically significant Myocardial infarction &lt; 6 month study entry Uncontrolled symptomatic congestive heart failure Ejection fraction institutional normal limit Any cardiac condition , opinion treat physician , would make protocol unreasonably hazardous patient ; Uncontrolled infection ; Pregnant lactating female ; History malignancy , except curatively treat basal cell carcinoma squamous cell carcinoma skin , carcinoma situ cervix . Subjects malignancy diseasefree least 5 year eligible . Have current active hepatic biliary disease ( exception subject Gilbert 's syndrome , asymptomatic gallstone , liver metastasis stable chronic liver disease per investigator assessment ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>brain metastasis</keyword>
	<keyword>ErbB2</keyword>
	<keyword>lapatinib</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>HYCAMTIN</keyword>
	<keyword>topotecan</keyword>
	<keyword>capecitabine</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>TYKERB</keyword>
	<keyword>XELODA</keyword>
</DOC>